Inovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder Cancer
October 16, 2017 07:00 ET
|
Inovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced initiation of a phase 1b/2 immuno-oncology trial to evaluate Genentech/Roche’s...